Blog

JTO and JTO CRR Achieve Strong Impact Factors in Oncology and Respiratory Medicine – IASLC

IASLC/LinkedIn

Jun 21, 2025, 14:31

JTO and JTO CRR Achieve Strong Impact Factors in Oncology and Respiratory Medicine – IASLC

International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:

“We’re proud to share the continued impact of the Journal of Thoracic Oncology (JTO) and JTO Clinical and Research Reports (JTO CRR)!

JTO’s Impact Factor is 20.8, ranking:

#3 of 108 in Respiratory Medicine

#13 of 326 in Oncology

JTO remains a top-tier, high-impact journal, leading the way in thoracic oncology through a strong multidisciplinary approach, rapid editorial process, and global collaboration.

Great news for JTO CRR, our open-access sister journal now has an Impact Factor of 3.5 (up from 3.0), placing it in the top half of oncology journals and top third in respiratory medicine!

We thank our authors, reviewers, editorial teams, and the IASLC community for their support.”

Read further.

More posts featuring IASLC.

cancer IASLC International Association for the Study of Lung Cancer Journal of Thoracic Oncology JTO JTO Clinical and Research Reports JTO CRR OncoDaily Oncology

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers